方舟子美国专利真相调查(ZT)# WaterWorld - 未名水世界
f*e
1 楼
本帖最后由 jshi6210 于 2010-7-13 11:58 编辑
方舟子美国专利真相调查(ZT)
万维读者网络>教育与学术
美国永久居民、所谓“打假斗士”方舟子常常在中美之间飞来飞去，他经营的美国网站
新语丝，据说每天点击五六十万。他何以为生、维持网站运营，是长期以来大家比较感
兴趣的一个问题。今天因为甘怀远同学的揭露，进行了一番饶有趣味的搜索。
1. 方舟子的博士后在索尔克生物研究院进行 方舟子，本名方是民，1967年9月生于
福建云霄县。1985年考入中国科技大学生物系。1990年本科毕业后赴美留学。1995年获
美国密歇根州立（Michigan State）大学生物化学博士学位，先后在罗切斯特（
Rochester）大学生物系、索尔克（Salk）生物研究院做博士后 …
scitech.people.com.cn/GB/25509/43690/index.html
2. 方舟子本人如此解释他的收入来源 方舟子：我把博士后研究时做的东西（克隆
了一个基因）申请了专利，得到一笔钱，可以维持基本生活费用。同时，我与人合作在
国内开了个专门向国外留学生卖书的网站，还可以拿到一笔钱。此外，我还在一家美国
生物信息公司兼任咨询科学家。总之，我还是攒了一些钱。 http://www.xys.org/xys/netters/Fang-Zhouzi/science/xinmin1.txt
3. 方舟子声称属于他本人所有的“克隆了一个基因”专利：
Cyclin T, A New HIV Target (S97041.pdf) Inventors Katherine Jones,
Ping Wei, Mitchell Garber, Shi-Min Fang Applications HIV, Drug
Discovery and Development After HIV has settled into a chromosome, a viral
protein called Tat (transactivating tranxion factor) accelerates the
production of new virus particles. Without Tat, an infection would not be
likely to get off the ground. Researchers have known that Tat does not
function alone, but requires help from a partner molecule in the cell.
However, the nature of the cellular partner remained elusive. This invention
covers the discovery of the molecule called cyclin T which appears to be
Tat’s partner. This discovery opens the door to developing a new class of
therapeutic agents for AIDS based on blocking the chain of events created by
the Tat-Cyclin T connection. References Genes & Development 11: 2593-
2599 (1997) Cell 92: 451-462 (1998) Genes & Development 12: 3512-3527
(1998) Mol. Cell. Biol. 20: 6958-6969 (2000) J. Biol. Chem. 275: 34314
-34319 (2000) Patent Status: U.S. Patent No. 6,270,956 issued August 7
, 2001 U.S. Patent No. 6,284,456 issued September 4, 2001 Australian
Patent No. 733100 License Terms: Exclusive or Nonexclusive licenses
available Reference Number: S97041 Contact: Anne-Marie Mueller -
Director, Office of Technology Management - 858.453.4100 x1275 - [email protected]
salk.edu http://www.salk.edu/otm/Abstracts/S97041.pdf
4. 索尔克生物研究院（Salk Institute）的专利律师（Patent Counsel）Sheila
Kirschenbaum回复甘怀远同学邮件摘要： “该专利属于索尔克研究院，如果使用与
此专利有关的技术，必须向本院申请许可。也许方先生没有明白，作为索尔克研究院的
雇员，通过劳动合同和索尔克专利政策，他把他的权利转给了索尔克研究院”。 “
The patents are owned and controlled by the Salk Institute and a license
from the Institute would be required to use the technology covered in the
patents.” “Perhaps Mr. Fang does not understand that as an employee of
Salk, he was required to assign his rights to the Salk Institute per his
employment agreement and Salk’s patent policy.” Sheila Kirschenbaum联系
方式：Tel: 858-453-4100 x1612, Mail: k**********[email protected]
5. 美国专利局查询记录
United States Patent 6,270,956 Jones , et al. August 7, 2001
Translational coactivator that interacts with Tat protein and regulates its
binding to TAR RNA, methods for modulating Tat transactivation, and uses
therefor Abstract In accordance with the present invention, a host cell
protein has been discovered which regulates Tat transactivation. The protein
is the first discovered constituent of the TAK/TEFb complex which
associates with the HIV Tat, via divalent cation metals, and is necessary
for the binding of Tat to TAR RNA. This protein, cyclin T1, is an 87 kDa
cyclin partner for the PITALRE kinase. It is further discovered that Tat
must interact with TAK in order to bind to TAR RNA with affinity and with
the appropriate sequence specificity that is observed in vivo. In accordance
with another aspect of the invention, xulations useful for modulation of
Tat transactivation have been developed. In addition, assays have been
developed for the identification of compounds useful to modulate the above-
described processes. Inventors: Jones; Katherine A. (Encinitas, CA), Wei;
Ping (Brookeville, MD), Garber; Mitchell (Woodland Hills, CA), Fang; Shi-Min
(San Diego, CA) Assignee: The Salk Institute for Biological Studies (La
Jolla, CA) Appl. No.: 09/126,980 Filed: July 30, 1998 United States
Patent 6,284,456 Jones , et al. September 4, 2001 Tranxional coactivator
that interacts with Tat protein and regulates its binding to TAR RNA,
methods for modulating Tat transactivation, and uses therefor Abstract In
accordance with the present invention, isolated nucleic acid encoding a host
cell protein that regulates Tat transactivation has been discovered. The
protein is the first discovered constituent of the TAK/TEFb complex which
associates with the HIV Tat, via divalent cation metals, and is necessary
for the binding of Tat to TAR RNA. This protein, cyclin T1, is an 87 kDa
cyclin partner for the PITALRE kinase. It is further discovered that Tat
must interact with TAK in order to bind to TAR RNA with affinity and with
the appropriate sequence specificity that is observed in vivo. In accordance
with another aspect of the invention, xulations useful for modulation of
Tat transactivation have been developed. In addition, assays have been
developed for the identification of compounds useful to modulate the above-
described processes. Inventors: Jones; Katherine A. (Encinitas, CA), Wei;
Ping (San Diego, CA), Garber; Mitchell (Woodland Hills, CA), Fang; Shi-Min (
San Diego, CA) Assignee: The Salk Institute for Biological Studies (La
Jolla, CA) Appl. No.: 09/476,482 Filed: December 30, 1999
6. 结论：
这个专利是四个人共同发明，而方舟子称“我把博士后研究时做的东西（克隆了一个基
因）申请了专利”云云，给大家得出他一个人做出了这个“东西”的印象； 方舟子
虽然作为四人之一参与了这个专利的发明工作，但是他和其他三位索尔克研究院的工作
人员一样，根本不是也不可能是这个专利的申请者和拥有者，他不可能从这个专利获取
任何合法利益，所谓“把博士后研究时做的东西（克隆了一个基因）申请了专利，得到
一笔钱，可以维持基本生活费用”，如果不是彻头彻尾的无耻谎言，就是彻头彻尾的刑
事犯罪——盗取属美国机构所有的该专利技术，化名在他国进行申请，以获取非法利益
。他的很可能非法经营的所谓“专门向国外留学生卖书的网站”，早在几个月前就悄无
声息地关闭了；而所谓“在一家美国生物信息公司兼任咨询科学家”，也很可能是完全
子虚乌有——多年没有从事任何科研教学工作的方舟子，还可能是“科学家”吗？
方舟子为什么要在他的收入问题上造假呢？他的真实收入来源是什么呢？
方舟子美国专利真相调查(ZT)
万维读者网络>教育与学术
美国永久居民、所谓“打假斗士”方舟子常常在中美之间飞来飞去，他经营的美国网站
新语丝，据说每天点击五六十万。他何以为生、维持网站运营，是长期以来大家比较感
兴趣的一个问题。今天因为甘怀远同学的揭露，进行了一番饶有趣味的搜索。
1. 方舟子的博士后在索尔克生物研究院进行 方舟子，本名方是民，1967年9月生于
福建云霄县。1985年考入中国科技大学生物系。1990年本科毕业后赴美留学。1995年获
美国密歇根州立（Michigan State）大学生物化学博士学位，先后在罗切斯特（
Rochester）大学生物系、索尔克（Salk）生物研究院做博士后 …
scitech.people.com.cn/GB/25509/43690/index.html
2. 方舟子本人如此解释他的收入来源 方舟子：我把博士后研究时做的东西（克隆
了一个基因）申请了专利，得到一笔钱，可以维持基本生活费用。同时，我与人合作在
国内开了个专门向国外留学生卖书的网站，还可以拿到一笔钱。此外，我还在一家美国
生物信息公司兼任咨询科学家。总之，我还是攒了一些钱。 http://www.xys.org/xys/netters/Fang-Zhouzi/science/xinmin1.txt
3. 方舟子声称属于他本人所有的“克隆了一个基因”专利：
Cyclin T, A New HIV Target (S97041.pdf) Inventors Katherine Jones,
Ping Wei, Mitchell Garber, Shi-Min Fang Applications HIV, Drug
Discovery and Development After HIV has settled into a chromosome, a viral
protein called Tat (transactivating tranxion factor) accelerates the
production of new virus particles. Without Tat, an infection would not be
likely to get off the ground. Researchers have known that Tat does not
function alone, but requires help from a partner molecule in the cell.
However, the nature of the cellular partner remained elusive. This invention
covers the discovery of the molecule called cyclin T which appears to be
Tat’s partner. This discovery opens the door to developing a new class of
therapeutic agents for AIDS based on blocking the chain of events created by
the Tat-Cyclin T connection. References Genes & Development 11: 2593-
2599 (1997) Cell 92: 451-462 (1998) Genes & Development 12: 3512-3527
(1998) Mol. Cell. Biol. 20: 6958-6969 (2000) J. Biol. Chem. 275: 34314
-34319 (2000) Patent Status: U.S. Patent No. 6,270,956 issued August 7
, 2001 U.S. Patent No. 6,284,456 issued September 4, 2001 Australian
Patent No. 733100 License Terms: Exclusive or Nonexclusive licenses
available Reference Number: S97041 Contact: Anne-Marie Mueller -
Director, Office of Technology Management - 858.453.4100 x1275 - [email protected]
salk.edu http://www.salk.edu/otm/Abstracts/S97041.pdf
4. 索尔克生物研究院（Salk Institute）的专利律师（Patent Counsel）Sheila
Kirschenbaum回复甘怀远同学邮件摘要： “该专利属于索尔克研究院，如果使用与
此专利有关的技术，必须向本院申请许可。也许方先生没有明白，作为索尔克研究院的
雇员，通过劳动合同和索尔克专利政策，他把他的权利转给了索尔克研究院”。 “
The patents are owned and controlled by the Salk Institute and a license
from the Institute would be required to use the technology covered in the
patents.” “Perhaps Mr. Fang does not understand that as an employee of
Salk, he was required to assign his rights to the Salk Institute per his
employment agreement and Salk’s patent policy.” Sheila Kirschenbaum联系
方式：Tel: 858-453-4100 x1612, Mail: k**********[email protected]
5. 美国专利局查询记录
United States Patent 6,270,956 Jones , et al. August 7, 2001
Translational coactivator that interacts with Tat protein and regulates its
binding to TAR RNA, methods for modulating Tat transactivation, and uses
therefor Abstract In accordance with the present invention, a host cell
protein has been discovered which regulates Tat transactivation. The protein
is the first discovered constituent of the TAK/TEFb complex which
associates with the HIV Tat, via divalent cation metals, and is necessary
for the binding of Tat to TAR RNA. This protein, cyclin T1, is an 87 kDa
cyclin partner for the PITALRE kinase. It is further discovered that Tat
must interact with TAK in order to bind to TAR RNA with affinity and with
the appropriate sequence specificity that is observed in vivo. In accordance
with another aspect of the invention, xulations useful for modulation of
Tat transactivation have been developed. In addition, assays have been
developed for the identification of compounds useful to modulate the above-
described processes. Inventors: Jones; Katherine A. (Encinitas, CA), Wei;
Ping (Brookeville, MD), Garber; Mitchell (Woodland Hills, CA), Fang; Shi-Min
(San Diego, CA) Assignee: The Salk Institute for Biological Studies (La
Jolla, CA) Appl. No.: 09/126,980 Filed: July 30, 1998 United States
Patent 6,284,456 Jones , et al. September 4, 2001 Tranxional coactivator
that interacts with Tat protein and regulates its binding to TAR RNA,
methods for modulating Tat transactivation, and uses therefor Abstract In
accordance with the present invention, isolated nucleic acid encoding a host
cell protein that regulates Tat transactivation has been discovered. The
protein is the first discovered constituent of the TAK/TEFb complex which
associates with the HIV Tat, via divalent cation metals, and is necessary
for the binding of Tat to TAR RNA. This protein, cyclin T1, is an 87 kDa
cyclin partner for the PITALRE kinase. It is further discovered that Tat
must interact with TAK in order to bind to TAR RNA with affinity and with
the appropriate sequence specificity that is observed in vivo. In accordance
with another aspect of the invention, xulations useful for modulation of
Tat transactivation have been developed. In addition, assays have been
developed for the identification of compounds useful to modulate the above-
described processes. Inventors: Jones; Katherine A. (Encinitas, CA), Wei;
Ping (San Diego, CA), Garber; Mitchell (Woodland Hills, CA), Fang; Shi-Min (
San Diego, CA) Assignee: The Salk Institute for Biological Studies (La
Jolla, CA) Appl. No.: 09/476,482 Filed: December 30, 1999
6. 结论：
这个专利是四个人共同发明，而方舟子称“我把博士后研究时做的东西（克隆了一个基
因）申请了专利”云云，给大家得出他一个人做出了这个“东西”的印象； 方舟子
虽然作为四人之一参与了这个专利的发明工作，但是他和其他三位索尔克研究院的工作
人员一样，根本不是也不可能是这个专利的申请者和拥有者，他不可能从这个专利获取
任何合法利益，所谓“把博士后研究时做的东西（克隆了一个基因）申请了专利，得到
一笔钱，可以维持基本生活费用”，如果不是彻头彻尾的无耻谎言，就是彻头彻尾的刑
事犯罪——盗取属美国机构所有的该专利技术，化名在他国进行申请，以获取非法利益
。他的很可能非法经营的所谓“专门向国外留学生卖书的网站”，早在几个月前就悄无
声息地关闭了；而所谓“在一家美国生物信息公司兼任咨询科学家”，也很可能是完全
子虚乌有——多年没有从事任何科研教学工作的方舟子，还可能是“科学家”吗？
方舟子为什么要在他的收入问题上造假呢？他的真实收入来源是什么呢？
